Ascletis Announces Inclusion in New Catalogue of China National Reimbursement Drug List (NRDL) of ASCLEVIR®/ GANOVO® Regimen, an All-oral Direct Anti-HCV Therapy
Retrieved on:
Friday, December 3, 2021
Patient, National Science Board, Cornerstone, CEO, Pegasys, Safety, PD-L1, FASN, Drug, CDC classification system for HIV infection, HKEX, CHB, GBM, Hong Kong Stock Exchange, Occupational Safety and Health Act 1994, Program, Danoprevir, Disease, HCV, National Healthcare, Guideline, Gannex, Degenerative disease, National Healthcare Security Administration, FXR, Cirrhosis, Liver cancer, Hepatitis B virus, PBC, Treatment, Management process, Insurance, Phase, Acne, HIV/AIDS, Conditional sentence, Infection, R, NASH, Hepatitis C, Public health, Mortality, Ravidasvir, Hospital, NRDL, Viral hepatitis, THR, Pharmaceutical industry, Vaccine
HANGZHOU, China and SHAOXING, China, Dec. 2, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that its all-oral direct anti-hepatitis C virus (HCV) ASCLEVIR® (Ravidasvir)/ GANOVO® (Danoprevir) regimen has been included in the Medicine Catalog for National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2021) (《国家基本医疗保险、工伤保险和生育保险药品目录（2021）年》) (the "National Reimbursement Drug List" or the "NRDL").
Key Points:
- The results from the Phase II/III clinical trials in China with the all-oral direct anti-HCV ASCLEVIR / GANOVO regimen showed a 99% cure rate in genotype 1 non-cirrhosis HCV patients.
- ASCLEVIR is a pan-genotypic NS5Ainhibitor with high genetic barrier to resistance, with a cure rate of 100% in patients with baseline NS5Aresistance.
- "The assessment by National Healthcare Security Administration ("NHSA") is based on multi-factors including efficacy, safety, economy, novelty and fairness.
- Ascletis will continue to support the country's healthcare system and contributes to the national 'Healthy China' strategy."